The active coenzyme form of vitamin B6, sold on the argument that it bypasses the liver conversion step required for pyridoxine. It is the form that actually does the work inside cells.
The pitch for P5P is that people with impaired liver conversion get more from the pre-activated form. The pharmacology is more awkward than that: circulating P5P is dephosphorylated before it can cross into cells and rephosphorylated inside, so the "pre-activated" advantage is largely notional for most people. Genuine conversion problems exist — some liver disease, some genetic conditions, and a rare vitamin-B6-dependent epilepsy where P5P specifically is the medicine — but they are clinical situations. Critically, the neuropathy risk that defines vitamin B6 has also been reported with P5P, so choosing this form is not a safety workaround.
Sold as
Capsule, Tablet, Sublingual tablet, Component of "activated" B-complex products
Also known as
P-5-P, PLP, Activated vitamin B6, Coenzymated B6
Regulation: Counts toward the same vitamin B6 upper limits — 12 mg/day per EFSA, 100 mg/day per the IOM — because it is the same vitamin. Australia's warning-label requirement for B6 applies to P5P products too, which is worth knowing since many "activated" formulas carry high doses.
What the research used
The amounts, forms and durations published trials of P5P (pyridoxal 5-phosphate) actually administered.
These are the amounts published trials administered — not a recommendation, and not a dose to copy. Trial participants were screened, supervised and given a characterised preparation. What is in a retail bottle is frequently not what was studied, and the amount that suits one person is not general advice.
Studied for Typical retail supplement
20–50 mg
Not enough
Capsule
Commonly sold at doses that exceed the European upper limit several times over. There is no evidence that the P5P form is safer than pyridoxine, and neuropathy reports exist for both.
Studied for Pyridoxine-refractory seizure disorders
30–50 mg/kg
Limited
Divided doses, specialist supervision
A specific paediatric neurological indication where P5P rather than pyridoxine is required. Included for context; it has no bearing on general supplement use and is not self-administered.
This is general information about food, not medical advice. It cannot diagnose, treat or replace guidance from a clinician who knows your history.
When it was taken
Each window says whether a trial compared it against an alternative, or whether it is convention and pharmacology. Most timing advice is the second kind.
None of the timings below were directly compared in a trial. They reflect how the research happened to dose, or what the pharmacology implies — which is not the same as a timing being better.
🍽️With food
Not enough
Usually taken with food for tolerability. No comparative timing data exist for this form.
Timing was not directly compared. This reflects convention or how the compound behaves in the body, not a trial showing this window works better.
The evidence in depth
Best supported: Not enough
What each association actually rests on, and the papers behind it. A rating describes the state of the research, not how promising the supplement sounds. How we rate evidence.
There is no trial evidence that P5P outperforms pyridoxine for any general outcome in people without a conversion disorder. Its superiority is a pharmacological argument that has not been tested clinically.
What may be going on: P5P is the coenzyme form used in transamination and decarboxylation reactions, but circulating P5P is dephosphorylated at the cell membrane and rephosphorylated inside — so the ingested form largely converges with pyridoxine.
Not enough evidence. Not enough human research to say anything useful yet.
No source is attached to this association yet, so it is rated not enough evidenceby default. It is listed because people commonly ask about it — not because there is evidence for it.
P5P is a cofactor for the enzymes that make serotonin, dopamine and GABA, which is the reason it is marketed for mood. No trial has shown that supplementing it changes mood in people who are not deficient.
Not enough evidence. Not enough human research to say anything useful yet.
Deep research mode adds each paper’s own conclusion and stated limitations.
Things to know
Interactions, contraindications and dose limits, most serious first. Concentrated extracts interact with medication in ways the whole plant does not, so this section carries more weight here than it does on a food page.
Too much
Same neuropathy risk as pyridoxine
Sensory peripheral neuropathy has been reported with P5P as well as pyridoxine, and blood P5P is the marker that correlates with the toxicity. Buying the "activated" form does not buy safety at high doses, despite marketing that implies it does.
Too much
Typical doses exceed the European upper limit
Products supplying 20–50 mg are common, against a 12 mg/day EFSA limit and a 1.3 mg/day RDA. Stacking an "activated" B-complex with another product carrying B6 compounds the exposure.
Interaction
Interacts with levodopa and anticonvulsants
Interacts withLevodopa, phenytoin, phenobarbital
As a vitamin B6 form it carries the same interactions — reduced effect of levodopa given without a decarboxylase inhibitor, and lowered phenytoin and phenobarbital levels.
Worth knowing
Stability and cost
P5P is less stable than pyridoxine hydrochloride and typically costs more. Neither is a reason to prefer it or avoid it — but the premium buys a pharmacological argument, not a demonstrated clinical advantage.